Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Preferred Dividend Payments (2021 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Preferred Dividend Payments for 7 consecutive years, with $344000.0 as the latest value for Q3 2025.

  • Quarterly Preferred Dividend Payments fell 15.27% to $344000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 28.8% year-over-year, with the annual reading at $1.2 million for FY2025, 28.8% down from the prior year.
  • Preferred Dividend Payments hit $344000.0 in Q3 2025 for Ani Pharmaceuticals, down from $407000.0 in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $407000.0 in Q2 2022 to a low of $190000.0 in Q4 2021.
  • Historically, Preferred Dividend Payments has averaged $388875.0 across 5 years, with a median of $406000.0 in 2022.
  • Biggest five-year swings in Preferred Dividend Payments: skyrocketed 114.21% in 2022 and later dropped 15.27% in 2025.
  • Year by year, Preferred Dividend Payments stood at $190000.0 in 2021, then soared by 114.21% to $407000.0 in 2022, then dropped by 0.25% to $406000.0 in 2023, then changed by 0.0% to $406000.0 in 2024, then fell by 15.27% to $344000.0 in 2025.
  • Business Quant data shows Preferred Dividend Payments for ANIP at $344000.0 in Q3 2025, $407000.0 in Q2 2025, and $406000.0 in Q1 2025.